Physician profile
Thomas Consolati
NPI 1326006362
$4,954.06
in general payments reported to CMS, 2019-2025
37 companies · $914 in 2025
The $914 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $611 · 2020: $440 · 2021: $723 · 2022: $562 · 2023: $977 · 2024: $726 · 2025: $914.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,617.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $528.76 | 2019-2025 | |
| Glaxosmithkline, LLC. | $526.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Neurocrine Biosciences, INC. | $503.51 | 2023-2025 | Ingrezza |
| Astrazeneca Pharmaceuticals LP | $367.88 | 2019-2025 | Airsupra |
| Janssen Pharmaceuticals, INC | $286.40 | 2019-2025 | Spravato, Xarelto |
| Merck Sharp & Dohme LLC | $276.38 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Astellas Pharma US INC | $262.36 | 2019-2025 | Veozah, Myrbetriq |
| Lilly USA, LLC | $247.97 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Novo Nordisk INC | $183.41 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $176.27 | 2022-2025 | Qulipta, Ubrelvy |
| Otsuka America Pharmaceutical, INC. | $167.17 | 2023-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Abbott Laboratories | $166.20 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $151.17 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $143.31 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $135.50 | 2023-2025 | Gemtesa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $118.88 | 2019-2023 | Eliquis |
| Lundbeck LLC | $110.90 | 2022-2025 | Rexulti |
| Amgen INC. | $108.78 | 2019-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $81.56 | 2019-2021 | |
| Exact Sciences Corporation | $49.64 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Indivior INC. | $32.85 | 2025 | Sublocade |
| Seqirus USA INC | $31.83 | 2019-2022 | |
| Ucb, INC. | $29.61 | 2023 | Nayzilam |
| Allergan, INC. | $27.28 | 2020 | |
| Avanir Pharmaceuticals, INC. | $24.00 | 2021 | |
| Amarin Pharma, INC. | $22.53 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $21.77 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $20.52 | 2025 | Zenpep |
| Axsome Therapeutics, INC. | $20.52 | 2025 | Auvelity |
| Daiichi Sankyo INC. | $20.00 | 2022 | |
| Scpharmaceuticals INC. | $18.60 | 2025 | |
| Mylan Specialty L.P. | $18.19 | 2022 | |
| Biogen, INC. | $17.25 | 2025 | Skyclarys |
| Depuy Synthes Sales INC. | $15.33 | 2019 | |
| Sanofi Pasteur INC. | $14.93 | 2025 | |
| Alkermes, INC. | $13.66 | 2025 | Vivitrol |
| Corium, LLC | $12.96 | 2024 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Consolati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.